What is Cycle Pharma?
Cycle Pharmaceuticals operates with a mission to address unmet medical needs in rare diseases, focusing on neurological, metabolic, and immunological areas. The company's strategy involves enhancing existing treatments, repurposing drugs, and creating novel formulations to improve patient outcomes. Beyond medication, Cycle Pharmaceuticals provides essential patient support services, including nutritional guidance and assistance programs, aiming to elevate the quality of life for patients and their caregivers. With a presence in both the UK and the United States, the company is positioned to impact a global patient population dealing with rare and often genetic conditions.
How much funding has Cycle Pharma raised?
Cycle Pharma has raised a total of $25M across 1 funding round:
Debt
$25M
Debt (2020): $25M with participation from Deutsche Bank AG
Key Investors in Cycle Pharma
Deutsche Bank AG
Deutsche Bank AG is a global financial services provider offering corporate and investment banking, private banking, and asset management. Their involvement suggests a significant debt financing component, likely supporting Cycle Pharma's operational expansion and development.
What's next for Cycle Pharma?
The substantial enterprise-level funding, particularly the recent strategic investment, signals a pivotal growth phase for Cycle Pharma. This capital infusion is expected to accelerate the company's research and development pipeline, expand its commercialization efforts for existing and pipeline therapies, and potentially broaden its geographical reach. The focus on rare diseases, coupled with a commitment to patient support, positions Cycle Pharma to capture significant market share in a specialized yet critical segment of the pharmaceutical industry. Future strategic partnerships or further financing rounds may be anticipated as the company scales its operations and brings new treatments to market.
See full Cycle Pharma company page
